Song Seung Hun, Kim Dae Keun, Sung Su Ye, Her Young Sun, Lee Ok Hee, Choi Myoung Hwa, Kim Hae Kyung, Lyu Sang Woo, Kim Dong Suk
Department of Urology, Fertility Center of CHA Gangnam Medical Center, CHA University College of Medicine, Seoul, Korea.
Department of Urology, CHA Fertility Center, Seoul Station, CHA University College of Medicine, Seoul, Korea.
World J Mens Health. 2019 May;37(2):219-225. doi: 10.5534/wjmh.180061. Epub 2018 Dec 26.
Sperm cryopreservation before cancer treatment is the most effective method to preserve the fertility of male patients. We present our 21 years experience with sperm cryopreservation for cancer patients, including an examination of semen quality, the current status of cryopreserved sperm, and the rate of sperm use for assisted reproductive technology (ART).
A total of 721 cancer patients at Fertility Center of CHA Gangnam Medical Center successfully performed sperm cryopreservation for fertility preservation from January 1996 to December 2016. Medical chart review was used to analyze patient age, marital status, cancer type, semen volume, sperm counts and motility, length of storage, and current banking status.
The major cancers of the 721 patients were leukemia (28.4%), lymphoma (18.3%), testis cancer (10.0%). The mean age at cryopreservation was 27.0 years, and 111 patients (15.4%) performed sperm cryopreservation during or after cancer treatment. The mean sperm concentration was 66.7±66.3 ×10⁶/mL and the mean sperm motility was 33.8%±16.3%. During median follow-up duration of 75 months (range, 1-226 months), 44 patients (6.1%) used their banked sperm at our fertility center for ART and 9 patients (1.2%) transferred their banked sperm to another center. The median duration from cryopreservation to use was 51 months (range, 1-158 months).
Sperm cryopreservation before gonadotoxic treatment is the most reliable method to preserve the fertility of male cancer patients. Sperm cryopreservation should be offered as a standard of care for all men planning cancer therapy.
癌症治疗前的精子冷冻保存是保留男性患者生育能力的最有效方法。我们介绍了我们21年来为癌症患者进行精子冷冻保存的经验，包括精液质量检查、冷冻保存精子的现状以及辅助生殖技术（ART）中精子的使用比例。
1996年1月至2016年12月期间，CHA江南医疗中心生育中心共有721例癌症患者成功进行了精子冷冻保存以保留生育能力。通过查阅病历分析患者年龄、婚姻状况、癌症类型、精液量、精子数量和活力、储存时间以及当前的储存状态。
721例患者的主要癌症类型为白血病（28.4%）、淋巴瘤（18.3%）、睾丸癌（10.0%）。冷冻保存时的平均年龄为27.0岁，111例患者（15.4%）在癌症治疗期间或之后进行了精子冷冻保存。平均精子浓度为66.7±66.3×10⁶/mL，平均精子活力为33.8%±16.3%。在中位随访时间75个月（范围1 - 226个月）内，44例患者（6.1%）在我们的生育中心使用储存的精子进行辅助生殖技术，9例患者（1.2%）将储存的精子转移至另一中心。从冷冻保存到使用的中位时间为51个月（范围1 - 158个月）。
性腺毒性治疗前的精子冷冻保存是保留男性癌症患者生育能力的最可靠方法。对于所有计划接受癌症治疗的男性，应将精子冷冻保存作为一种标准治疗措施。
